REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot181610.32687/1561-5936-2025-29-3-213-220Original ArticleMain areas and prospects for using artificial intelligence and machine learning to accelerate the development of new medicinesKoshechkinKonstantin Aleksandrovichk.koshechkin@lpt.digitalLavrentevaLarisa IvanovnaLavl2004@mail.ruRomanovPhilip Aleksandrovichrfa2010@ya.ruYavorskyAlexandr Nikolaevichmail.ruEurasian Academy of Good Practices, Moscow, RussiaYaroslavl State Medical University of the Ministry of Healthcare of the Russian Federation, Yaroslavl, RussiaAssociation of Participants in the Circulation of Medicines and Medical Devices, Moscow, Russia15122025321322017102025Copyright © 2025,2025The article is dedicated to the directions and prospects of using artificial intelligence (AI) and machine learning (ML) in the development of new medicines. Innovative approaches have been presented that radically transform traditional processes of drug discovery and development. The main applications of AI/ML are presented: target identification and validation, molecular design, prediction of drug compound properties, and laboratory process automation. Technological solutions in this field are presented, such as Direct-to-Biology platforms, CRISPR technologies, high throughput imaging, and generative AI models. The key advantages of implementing AI/ML include accelerating medicines development, reducing costs, enhancing prediction accuracy, and expanding molecular design capabilities. To realize this potential, it is necessary to continue investing in technology and training specialists with an interdisciplinary profile. The integration of AI into research opens up new prospects for developing innovative, personalized treatment methods.overview, artificial intelligence, machine learning, medicines developобзор, искусственный интеллект, машинное обучение, разработка лекарственных средствSimonyan K., Zisserman A. Very deep convolutional networks for large-scale image recognition. arXiv preprint arXiv:1409.1556. 2014.Drug Discovery — ELRIG [Electronic resource]. URL: https://elrig.org/portfolio/drug-discovery-2024/ (accessed: 02th January 2025).Sheikh M, Iqra F, Ambreen H, Pravin KA, Ikra M, Chung YS Integrating artificial intelligence and high-throughput phenotyping for crop improvement. J. Integr. Agric. 2024;(23):1787—1802.Fang S, Wei R, Cui Y, Su L. Advancing AI protein structure prediction and design: from amino acid “bones” to new era of all-atom “flesh”. Green Carbon. 2024;(2):209—210.Pioneering TechBio Solutions in Drug Discovery. Recursion [Electronic resource]. Available from: https://www.recursion.com/ (Аccessed: 02th January 2025).Stevens R, Bendito-Mol E, Battersby DJ, Miah AH, Wellaway N, Law RP at all. Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs. Journal of medicinal chemistry. 2022;66(22):15437—15452. DOI: 10.1021/acs.jmedchem.3c01604Abbasi AF, Asim MN, Dengel A. Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR. J Transl Med. 2025;23(1):153. DOI: 10.1186/s12967-024-06013-wAdvancing Gene Editing with ePsCas9 Technology [Electronic resource]. Available from: https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/advancing-gene-editing-with-epscas9-technology.html (Аccessed: 02th January 2025).Degtev D, Bravo J, Emmanouilidi A, Zdravković A, Choong O, Touza J et al. Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles. Nature Communications. 2024;15(1):1—15.On the CRISPR horizon: democratising access to genome-editing technologies. Available from: https://www.drugtargetreview.com/article/107337/on-the-crispr-horizon-democratising-access-to-genome-editing-technologies/ (Accessed: 02th January 2025).Constructive Bio. Available from: https://www.constructive.bio/. (Accessed: 02th January 2025).Chen L, Xin X, Zhang Y, Li S, Zhao X, Li S. et al. Advances in Biosynthesis of Non-Canonical Amino Acids (ncAAs) and the Methods of ncAAs Incorporation into Proteins. Molecules. 2023;28(18):6745.Chen Y, Jin S, Zhang M, Hu Y, Wu KL, Chung A. et al. Unleashing the potential of noncanonical amino acid biosynthesis to create cells with precision tyrosine sulfation. Nat Commun. 2022;(13):5434.Automating Discovery: Laboratory Automation, High Throughput Experimentation, Diagnostics and Laboratory Robotics/AI. Available from: https://eu-robotics.net/2024-09-fll-white-paper-launched-on-lab-robotics/ (accessed: 02th January 2025).Towards a research roadmap for laboratory robotics — 2024 — Wiley Analytical Science. Available from: https://analyticalscience.wiley.com/content/article-do/towards-research-roadmap-laboratory-robotics (accessed: 02th January 2025).Royall P. Using Robotics in Laboratories During the COVID-19 Outbreak: A Review. IEEE Robotics & Automation Magazine.12641 PDFs | Review articles in LABORATORY AUTOMATION. Available from: https://www.researchgate.net/topic/Laboratory-Automation/publications (accessed: 02th January 2025).Li H, Li T, Quang D, Guan Y. Network Propagation Predicts Drug Synergy in Cancers. Cancer Res. 2018;78(18):5446—5457.Bestas B, Wimberger S, Degtev D, Madsen А, Rottner ФА., Karisson F. at al. A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo. Nat Commun. 2023;14(1):5474.Reimagining Drug Discovery Process with AI — Isomorphic Labs. Available from: https://www.isomorphiclabs.com/ (Аccessed: 02th January 2025).Roerden M, Castro AB, Cui Y, Harake N, Kim B, Dye J, Roerden M et al. Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. J Immunother Cancer. 2024;12(11):e010249.Litchfield K, Augustine M, Nene N, Fu H, Pinder C, Ligamari L et al. Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation. Biomedical Foundation Models — IBM Research [Internet]. 2024 Nov; Available from: https://research.ibm.com/projects/biomedical-foundation-models. DOI:10.21203/rs.3.rs-5499857/v1Biomedical Foundation Models — IBM Research [Electronic resource]. URL: https://research.ibm.com/projects/biomedical-foundation-models (accessed: 02.01.2025).United Kingdom — IBM Research. Available from: https://research.ibm.com/labs/uk (accessed: 02th January 2025).Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Mol Pharm. 2016;13(7):2524—2530. DOI: 10.1021/acs.molpharmaceut.6b00248Insilico Medicine. Available from: https://insilico.com/ (Accessed: 02th January 2025).Kamya P, Ozerov IV, Pun FW, et al. PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery. J Chem Inf Model. 2024;64(10):3961—3969. DOI: 10.1021/acs.jcim.3c01619Ivanenkov YA, Polykovskiy D, Bezrukov D, et al. Chemistry42: An AI-Driven Platform for Molecular Design and Optimization. J Chem Inf Model. 2023;63(3):695—701. DOI: 10.1021/acs.jcim.2c01191Lu M, Yin J, Zhu Q, Lin G, Mou M, Liu F, et al. Artificial Intelligence in Pharmaceutical Sciences. Engineering [Internet]. 2023 Aug [cited 2024 Jul 4]; 27: 37—69. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2095809923001649.Levin JM, Oprea TI, Davidovich S, Clozel T, Overington J, Vanhaelen Q et al. Artificial intelligence, drug repurposing and peer review. Nat Biotechnol. 2020;38(10):1127—1131. DOI: 10.1038/s41587-020-0686-xRXRX3: Phenomics Map of Biology. Available from: https://www.rxrx.ai/rxrx3 (Accessed: 02th January 2025).